Covington Capital Management’s GSK GSK Stock Holding History

Covington Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$65K	Sell	2,220 -200	-8%	-$7.58K	﹤0.01%	523
2022 Q2	$132K	Sell	2,420 -23,262	-91%	-$1.28M	0.01%	421
2022 Q1	$904K	Buy	25,682 +23,302	+979%	+$1.27M	0.03%	246
2021 Q4	$131K	Buy	2,380 +820	+53%	+$42.7K	﹤0.01%	409
2021 Q3	$75K	Hold	1,560	–	–	﹤0.01%	487
2021 Q2	$78K	Buy	1,560 +160	+11%	+$7.69K	﹤0.01%	479
2021 Q1	$62K	Sell	1,400 -120	-8%	-$5.45K	﹤0.01%	452
2020 Q4	$70K	Sell	1,520 -120	-7%	-$5.51K	﹤0.01%	431
2020 Q3	$77K	Buy	1,640 +40	+3%	+$2K	﹤0.01%	407
2020 Q2	$82K	Buy	1,600 +120	+8%	+$6.16K	﹤0.01%	390
2020 Q1	$70K	Sell	1,480 -240	-14%	-$12.8K	﹤0.01%	377
2019 Q4	$101K	Sell	1,720 -16,880	-91%	-$939K	0.01%	375
2019 Q3	$679K	Buy	18,600 +16,880	+981%	+$868K	0.04%	210
2019 Q2	$86K	Sell	1,720 -16,840	-91%	-$845K	0.01%	371
2019 Q1	$662K	Buy	18,560 +17,160	+1,226%	+$857K	0.04%	199
2018 Q4	$67K	Buy	+1,400	New	+$68.9K	﹤0.01%	383
2017 Q4	–	Sell	-620	Closed	-$31K	–	814
2017 Q3	$31K	Buy	+620	New	+$31.5K	﹤0.01%	484

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Covington Capital Management's GSK Position: Q3 2022 in Review

Covington Capital Management reduced its GSK (GSK) stake by 8.3% in Q3 2022, selling an estimated $7.58K and leaving 2,220 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

Covington Capital Management first reported a position in GSK in Q3 2017 and has held it in 17 quarters since. The position peaked at $904K in Q1 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Covington Capital Management held 2,220 shares of GSK worth $65K as of Q3 2022.
Covington Capital Management sold 200 GSK shares in Q3 2022, an estimated $7.58K.
GSK made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #523 holding.
Covington Capital Management first reported a position in GSK in Q3 2017 and has held it in 17 quarters since.
Covington Capital Management's GSK position peaked at $904K in Q1 2022.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.